Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?
- Cite this article as:
- Brock, C.S., Meikle, S.R. & Price, P. Eur J Nucl Med (1997) 24: 691. doi:10.1007/BF00841411
Fluoro-deoxyglucose (FDG) is a metabolic marker, which follows the same route into cells as that of glucose, and it can be radiolabelled wich fluorine-18,18F-FDG making it suitable for imaging with positron emission tomography (PET). The fact that rapidly proliferating cells such as tumour cells accumulate18F-FDG more avidly than those with a normal turnover rate has given rise to its potential in oncology. The rationale and previous published uses of18F-FDG in oncology are reviewed, together with the various analysis techniques and associated methodological difficulties.